hr

Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Top

The Honorary Editor-in-Chief Prof. Shukui Qin and Editorial Board Member Prof. Amedeo Lonardo of Hepatoma Research Named to Clarivate’s 2022 "Highly Cited Researchers" List

Published on: 18 Nov 2022 Viewed: 72

On November 15, 2022, Clarivate released the list of "Highly Cited Researchers in 2022" -- individuals at universities, research institutes and commercial organizations who have demonstrated significant roles in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information (ISI)TM at Clarivate. Of the world's population of scientists and social scientists, Highly Cited Researchers™ are 1 in 1,000 and finally top 6,938 Highly Cited Researchers in 2022 are named to the list. Delightedly, Honorary Editor-in-Chief Prof. Shukui Qin and Editorial Board member Prof. Amedeo Lonardo of Hepatoma Research are awarded the designation. The Editorial Office of Hepatoma Research extends sincere congratulations to Prof. Qin and Prof. Lonardo!

Prof. Shukui Qin

Highly Cited Researcher in the field of Clinical Medicine – 2022

Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Shukui Qin is the Deputy Director of People's Liberation Army (PLA) 81 Hospital (Nanjing, China), Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the Executive Member of the Asian Clinical Oncology Society (ACOS), Chair of Chinese Society of Clinical Oncology (CSCO), Council Member of PLA Medical Science Commission (and the Executive Member of its oncology society), Member of the Oncology Branch of Chinese Medical Association, Expert Committee Member of National Tumor Standardized Diagnosis and Treatment of Ministry of Health (and also the leader of the Liver Cancer Expert Panel and Cancer Pain Expert Panel), Vice President of Beijing Xisike Clinical Oncology Research Foundation, and Member of Chinese Anti-cancer Association (CACA) (and the Vice Chairman of the Committee of Rehabilitation and Palliative Care affiliated to CACA). After decades of clinical practice and scientific research, Prof. Qin has accumulated rich experiences in the medical treatment of gastrointestinal cancers and their bone metastases. Prof. Qin has published over 400 articles in peer-reviewed journals. He has been granted a number of professional awards at the ministerial and provincial levels (including four first-class prizes, two second-class prizes, seven third-class prizes, and two fourth-class prizes). He is granted special government allowance by the State Council of China and the PLA. Currently, he is the Editor-in-Chief of two highly-rated journals (Journal of Clinical Oncology and Clinical Oncology Tribune) in China.


Prof. Amedeo Lonardo

Highly Cited Researcher in the field of Cross-Field – 2022

Operating Unit of Metabolic Syndrome, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy. 

Amedeo Lonardo graduated from the University of Campania "Luigi Vanvitelli" in Italy, where he specialized in Gastroenterology and Digestive Endoscopy. Subsequently, he specialized in Pediatrics and Internal Medicine at the University of Modena and Reggio Emilia. Since April 1988, he has carried out his entire professional career in Modena, first at the Sant'Agostino Hospital, then at the Policlinico and later at the Baggiovara Civil Hospital since its opening. In 2017, Amedeo Lonardo obtained his qualification for National Scientific Qualification in Internal Medicine and Gastroenterology. His main lines of study pertaining to the metabolic pathology of the liver, i.e., the "fatty liver", which is an indicator but also the cause of cardio-metabolic alterations such as diabetes, hypertension and dyslipidemia. He studied the many clinical manifestations, associations, and complications of fatty liver. Over the past 10 years, he has been ranked in the top 0.012% of scholars studying "fatty liver" worldwide (Expertscape). He was on the board of the scientific journal World Journal of Gastroenterology from 2018-2021. He was recognized as an exceptional reviewer for Preventing Chronic Disease between January and December 2021. Furthermore, he has been ranked the top reviewer in Clinical Medicine since 2018, according to the Web of Science.

Without the generous support of our Editorial Board members, Hepatoma Research would not have been where it is today. We will maintain our unremitting faith and enthusiasm to work with our scholars to build Hepatoma Research an influential international journal in the field!

For the full list of Highly Cited Researchers 2022: https://clarivate.com/highly-cited-researchers/.

Respectfully submitted by Delphine Wong, the Science Editor of Hepatoma Research


© 2016-2022 OAE Publishing Inc., except certain content provided by third parties